Cargando…

The future of cancer immunotherapy: DNA vaccines leading the way

Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer. Plasmid DNA immunizations have shown a favorable safety pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandya, Aanshi, Shah, Yesha, Kothari, Nirjari, Postwala, Humzah, Shah, Aayushi, Parekh, Priyajeet, Chorawala, Mehul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251337/
https://www.ncbi.nlm.nih.gov/pubmed/37294501
http://dx.doi.org/10.1007/s12032-023-02060-3
_version_ 1785055925612052480
author Pandya, Aanshi
Shah, Yesha
Kothari, Nirjari
Postwala, Humzah
Shah, Aayushi
Parekh, Priyajeet
Chorawala, Mehul R.
author_facet Pandya, Aanshi
Shah, Yesha
Kothari, Nirjari
Postwala, Humzah
Shah, Aayushi
Parekh, Priyajeet
Chorawala, Mehul R.
author_sort Pandya, Aanshi
collection PubMed
description Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer. Plasmid DNA immunizations have shown a favorable safety profile and there occurs induction of generalized as well as tailored immune responses in preclinical and early-phase clinical experiments. However, these vaccines have notable limitations in immunogenicity and heterogeneity and these require refinements. DNA vaccine technology has been focusing on improving vaccine efficacy and delivery, with parallel developments in nanoparticle-based delivery systems and gene-editing technologies such as CRISPR/Cas9. This approach has showcased great promise in enhancing and tailoring the immune response to vaccination. Strategies to enhance the efficacy of DNA vaccines include the selection of appropriate antigens, optimizing insertion in a plasmid, and studying combinations of vaccines with conventional strategies and targeted therapies. Combination therapies have attenuated immunosuppressive activities in the tumor microenvironment and enhanced the capability of immune cells. This review provides an overview of the current framework of DNA vaccines in oncology and focuses on novel strategies, including established combination therapies and those still under development.The challenges that oncologists, scientists, and researchers need to overcome to establish DNA vaccines as an avant-garde approach to defeating cancer, are also emphasized. The clinical implications of the immunotherapeutic approaches and the need for predictive biomarkers have also been reviewed upon. We have also tried to extend the role of Neutrophil extracellular traps (NETs) to the DNA vaccines. The clinical implications of the immunotherapeutic approaches have also been reviewed upon. Ultimately, refining and optimizing DNA vaccines will enable harnessing the immune system's natural ability to recognize and eliminate cancer cells, leading the world towards a revolution in cancer cure.
format Online
Article
Text
id pubmed-10251337
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-102513372023-06-12 The future of cancer immunotherapy: DNA vaccines leading the way Pandya, Aanshi Shah, Yesha Kothari, Nirjari Postwala, Humzah Shah, Aayushi Parekh, Priyajeet Chorawala, Mehul R. Med Oncol Review Article Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer. Plasmid DNA immunizations have shown a favorable safety profile and there occurs induction of generalized as well as tailored immune responses in preclinical and early-phase clinical experiments. However, these vaccines have notable limitations in immunogenicity and heterogeneity and these require refinements. DNA vaccine technology has been focusing on improving vaccine efficacy and delivery, with parallel developments in nanoparticle-based delivery systems and gene-editing technologies such as CRISPR/Cas9. This approach has showcased great promise in enhancing and tailoring the immune response to vaccination. Strategies to enhance the efficacy of DNA vaccines include the selection of appropriate antigens, optimizing insertion in a plasmid, and studying combinations of vaccines with conventional strategies and targeted therapies. Combination therapies have attenuated immunosuppressive activities in the tumor microenvironment and enhanced the capability of immune cells. This review provides an overview of the current framework of DNA vaccines in oncology and focuses on novel strategies, including established combination therapies and those still under development.The challenges that oncologists, scientists, and researchers need to overcome to establish DNA vaccines as an avant-garde approach to defeating cancer, are also emphasized. The clinical implications of the immunotherapeutic approaches and the need for predictive biomarkers have also been reviewed upon. We have also tried to extend the role of Neutrophil extracellular traps (NETs) to the DNA vaccines. The clinical implications of the immunotherapeutic approaches have also been reviewed upon. Ultimately, refining and optimizing DNA vaccines will enable harnessing the immune system's natural ability to recognize and eliminate cancer cells, leading the world towards a revolution in cancer cure. Springer US 2023-06-09 2023 /pmc/articles/PMC10251337/ /pubmed/37294501 http://dx.doi.org/10.1007/s12032-023-02060-3 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Pandya, Aanshi
Shah, Yesha
Kothari, Nirjari
Postwala, Humzah
Shah, Aayushi
Parekh, Priyajeet
Chorawala, Mehul R.
The future of cancer immunotherapy: DNA vaccines leading the way
title The future of cancer immunotherapy: DNA vaccines leading the way
title_full The future of cancer immunotherapy: DNA vaccines leading the way
title_fullStr The future of cancer immunotherapy: DNA vaccines leading the way
title_full_unstemmed The future of cancer immunotherapy: DNA vaccines leading the way
title_short The future of cancer immunotherapy: DNA vaccines leading the way
title_sort future of cancer immunotherapy: dna vaccines leading the way
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251337/
https://www.ncbi.nlm.nih.gov/pubmed/37294501
http://dx.doi.org/10.1007/s12032-023-02060-3
work_keys_str_mv AT pandyaaanshi thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT shahyesha thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT kotharinirjari thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT postwalahumzah thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT shahaayushi thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT parekhpriyajeet thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT chorawalamehulr thefutureofcancerimmunotherapydnavaccinesleadingtheway
AT pandyaaanshi futureofcancerimmunotherapydnavaccinesleadingtheway
AT shahyesha futureofcancerimmunotherapydnavaccinesleadingtheway
AT kotharinirjari futureofcancerimmunotherapydnavaccinesleadingtheway
AT postwalahumzah futureofcancerimmunotherapydnavaccinesleadingtheway
AT shahaayushi futureofcancerimmunotherapydnavaccinesleadingtheway
AT parekhpriyajeet futureofcancerimmunotherapydnavaccinesleadingtheway
AT chorawalamehulr futureofcancerimmunotherapydnavaccinesleadingtheway